We are in the advanced stages of developing two fermentation-based Active Pharmaceutical Ingredients, namely, Tacrolimus and Sirolimus, that have clinical application within the field of immunology, oncology, and rare diseases. Our expected timeline for commercialization is the second quarter of 2024.
Tacrolimus is a biosynthetic macrolide with immunosuppressive properties. It is a calcineurin inhibitor that inhibits the Nuclear factor NFAT, thereby decreasing the synthesis of inflammatory cytokines.
Tacrolimus is used as primary therapy for renal and hepatic transplantation with 10-100 times higher efficacy than Cyclosprine.
Therapeutic Relevance
Sirolimus, also known as Rapamycin, is a biosynthetic small molecule with immunosuppressive, anti-fungal, and anti-proliferative properties. It is an mTOR inhibitor that blocks a protein complex called mTOR (mammalian target of Rapamycin), resulting in the prevention of cell-cycle progression from G1 to S phase downstream.
Therapeutic Relevance